REVIEWS |
|
A.I. Sinopalnikov
Management of patients with community-acquired pneumonia in outpatient settings
|
8-18 |
|
S.L. Babak, M.V. Gorbunova, A.G. Malyavin
Algorithm of respiratory support for COVID-19 patients
|
19-26 |
|
E.I. Kakhiani (1), N.A. Korobkov (1), V.V. Vasiliev (1, 2), E.S. Romanova (1)
Therapeutic and diagnostic aspects of the new coronavirus infection COVID-19 in obstetric practice
|
27-37 |
|
|
Yu.G. Belotserkovskaya (1), S.S. Lebedev (1), D.V. Vakatov (2), I.A. Demina (2), O. N. Sakara (2), A.G. Romanovskikh (1), I.P. Smirnov (1)
COVID-19: selected clinical aspects through the prism of practical experience
|
38-51 |
|
O.V. Fesenko (1), O.A. Sibiryakova (1), S.N. Shvayko (2)
Treatment of a new coronavirus infection (COVID-19): opportunities and limitations
|
52-60 |
|
A.I. Sinopalnikov
Formula for successful chronic obstructive pulmonary disease control
|
61-71 |
ORIGINAL ARTICLES |
|
E.A. Orlova, E.M. Kostina, O.A. Kulikova
Clinical experience of sublingual allergen-specific immunotherapy of allergic rhinitis in a coronavirus pandemic
|
72-79 |
|
A.B. Pirogov, A.G. Prikhodko, N.L. Perelman, E.Yu. Afanasyeva, E.Yu. Kochegarova, L.Yu. Oshur, J.M. Perelman
Possibilities of achieving of bronchial asthma control against the background of baseline therapy with beclometasone/formoterol extrafine fixed combination: an open observational prospective study
|
80-87 |
|
E.M. Kostina (1), E.Yu. Trushina (1), E.A. Orlova (1), N.I. Baranova (1), O.A. Levashova (2)
The role of leukotrienes in the pathogenesis of inflammation in patients with different phenotypes of bronchial asthma and chronic obstructive pulmonary disease
|
88-93 |
|
D.F. Sergienko, P.B. Khishtilova
Bronchopulmonary dysplasia in children in terms of genetic variability of the vitamin D receptor
|
94-99 |
|
I.V. Vyazovaya, S.D. Ikhsanov, I.A. Averina
Features of the course of chronic lung diseases in children at the present stage
|
100-105 |
|
E.Yu. Trushina, E.M. Kostina
Indications for the administration of inhaled glucocorticosteroids in patients with chronic obstructive pulmonary disease
|
106-110 |
|
R.A. Bontsevich (1, 2, 3), A.V. Adonina (1, 2), A.V. Mikhno (2, 4), D.I. Kutsenko (2), G.A. Batishcheva (5), Yu.M. Dronova (5), G.G. Ketova (6), V.O. Barysheva (6), E.V. Luchinina (7), E.V. Mironenko (8), G.M. Bikkinina (9), T.G. Pokrovskaya (1)
Bronchial asthma: assessment of knowledge of senior students. Final results of the ASSA-II study
|
111-118 |
|
E.A. Orlova (1), E.M. Kostina (1), O.A. Kulikova (1), O.A. Levashova (2), S.A. Sokolov (3)
Comparative assessment of leukotriene levels in different forms of rhinitis
|
120-124 |
|
|
N.M. Nenasheva (1), S.V. Fedosenko (2, 3), E.N. Barabanova (3)
Efficacy and safety of mepolizumab in patients with bronchial asthma in real clinical practice
|
125-132 |
|
D.V. Bestaev (1), Z.S. Brtsieva (1), S.A. Ktsoeva (1), L.M. Khutieva (1), N.N. Burduli (1), O.T. Kotsoeva (1), T.D. Bestaeva (2)
Some aspects of interstitial lung disease associated with leflunomide therapy in patients with rheumatoid arthritis
|
133-135 |
Русский
